Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558788 | 0.85 | NOTUM (0.52) | NOTUMCYP19A1ELOVL1CYP1A1HTT | |
| SCHEMBL17984479 | 0.81 | NOTUM (0.48) | NOTUMCYP19A1ELOVL1CYP1A1 | |
| SCHEMBL9756479 | 0.81 | NOTUM (0.66) | NOTUMCYP19A1ELOVL1AKR1C3AKR1C2 | |
| SCHEMBL2387626 | 0.77 | NOTUM (0.56) | NOTUMCYP19A1 | |
| SCHEMBL1574429 | 0.76 | AKR1C3 (0.58) | HTR1AADRA1AAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL4488094 | 0.74 | SMN1; SMN2 (0.48) | ELOVL1HTR1AADRA1AAKR1C3AKR1C2 | |
| SCHEMBL12794021 | 0.73 | NOTUM (1.00) | NOTUMCYP19A1 | |
| SCHEMBL462839 | 0.72 | NOTUM (0.56) | NOTUMCYP19A1 | |
| SCHEMBL7336731 | 0.71 | NOTUM (0.46) | NOTUMCYP19A1 | |
| SCHEMBL1226388 | 0.71 | LMNA (0.57) | CYP19A1HTR1AADRA1AAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | NOTUM 1064/4885CYP19A1 222/4885ELOVL1 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.